MicroRNA Antagonism of the Picornaviral Life Cycle: Alternative Mechanisms of Interference

por Kelly, Elizabeth J., Hadac, Elizabeth M., Cullen, Bryan R., Russell, Stephen J.
Publicado 2010

Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences

por O’Toole, Áine, Pybus, Oliver G., Abram, Michael E., Kelly, Elizabeth J., Rambaut, Andrew
Publicado 2022

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study

por Morehouse, Christopher A, Ahani, Bahar, Aksyuk, Anastasia A, Brady, Tyler, Tuffy, Kevin M, Ji, Hong, Kelly, Elizabeth J, Wilkins, Deidre
Publicado 2023

Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration

por Saini, Yogesh, Dang, Hong, Livraghi-Butrico, Alessandra, Kelly, Elizabeth J, Jones, Lisa C, O’Neal, Wanda K, Boucher, Richard C
Publicado 2014

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination

por Cohen, Taylor S., Kelly, Elizabeth J., Nylander, Sven, Bansal, Himanshu, Jepson, Brett M., Bhuyan, Prakash, Sobieszczyk, Magdalena E., Falsey, Ann R.
Publicado 2022

One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan

por Ishikawa, Kensuke, Nascimento, Maria-Claudia, Asano, Michiko, Hirata, Hajime, Itoh, Yohji, Kelly, Elizabeth J., Matsui, Akiko, Olsson, Urban, Shoemaker, Kathryn, Green, Justin
Publicado 2023

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

por Asano, Michiko, Okada, Hiroshi, Itoh, Yohji, Hirata, Hajime, Ishikawa, Kensuke, Yoshida, Erika, Matsui, Akiko, Kelly, Elizabeth J., Shoemaker, Kathryn, Olsson, Urban, Vekemans, Johan
Publicado 2022

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Ph...

por Wilkins, Deidre, Hamrén, Ulrika Wählby, Chang, Yue, Domachowske, Joseph B, Englund, Janet A, Muller, William J, Leach, Amanda, Villafana, Tonya L, Kelly, Elizabeth J
Publicado 2023

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination

por Wilkins, Deidre, Aksyuk, Anastasia A, Ruzin, Alexey, Tuffy, Kevin M, Green, Tina, Greway, Rebecca, Fikes, Brittany, Bonhomme, Cyrille J, Esser, Mark T, Kelly, Elizabeth J
Publicado 2022

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

por Brady, Tyler, Cayatte, Corinne, Roe, Tiffany L., Speer, Scott D., Ji, Hong, Machiesky, LeeAnn, Zhang, Tianhui, Wilkins, Deidre, Tuffy, Kevin M., Kelly, Elizabeth J.
Publicado 2023

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study

por Levin, Myron J, Ustianowski, Andrew, Thissen, Jesse, Seegobin, Seth, Beavon, Rohini, Dey, Kanika, Kelly, Elizabeth J, Near, Karen A, Streicher, Katie, Kiazand, Alexandre, Esser, Mark T
Publicado 2023

AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection

por Aksyuk, Anastasia A., Bansal, Himanshu, Wilkins, Deidre, Stanley, Ann Marie, Sproule, Stephanie, Maaske, Jill, Sanikommui, Satya, Hartman, William R., Sobieszczyk, Magdalena E., Falsey, Ann R., Kelly, Elizabeth J.
Publicado 2022

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants

por Roe, Tiffany L., Brady, Tyler, Schuko, Nicolette, Nguyen, Amy, Beloor, Jagadish, Guest, Johnathan D., Aksyuk, Anastasia A., Tuffy, Kevin M., Zhang, Tianhui, Streicher, Katie, Kelly, Elizabeth J., Kijak, Gustavo H.
Publicado 2023

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T(H)1 response with a diverse TCR repertoire

por Swanson, Phillip A., Padilla, Marcelino, Hoyland, Wesley, McGlinchey, Kelly, Fields, Paul A., Bibi, Sagida, Faust, Saul N., McDermott, Adrian B., Lambe, Teresa, Pollard, Andrew J., Durham, Nicholas M., Kelly, Elizabeth J.
Publicado 2021

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

por Tuffy, Kevin M, Ahani, Bahar, Aksyuk, Anastasia A, Avila, Miles, Brady, Tyler, Kijak, Gustavo H, Koh, Gavin, Levin, Myron J, Roe, Tiffany L, Schuko, Nicolette, Thissen, Jesse, Ustianowski, Andrew, Zhang, Tianhui, Kelly, Elizabeth J, Streicher, Katie
Publicado 2023

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

por Brady, Tyler, Zhang, Tianhui, Tuffy, Kevin M., Haskins, Nantaporn, Du, Qun, Lin, Jia, Kaplan, Gilad, Novick, Steven, Roe, Tiffany L., Ren, Kuishu, Rosenthal, Kim, McTamney, Patrick M., Abram, Michael E., Streicher, Katie, Kelly, Elizabeth J.
Publicado 2022

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

por Feng, Shuo, Phillips, Daniel J., White, Thomas, Sayal, Homesh, Aley, Parvinder K., Bibi, Sagida, Dold, Christina, Fuskova, Michelle, Gilbert, Sarah C., Hirsch, Ian, Humphries, Holly E., Jepson, Brett, Kelly, Elizabeth J., Plested, Emma, Shoemaker, Kathryn, Thomas, Kelly M., Vekemans, Johan, Villafana, Tonya L., Lambe, Teresa, Pollard, Andrew J., Voysey, Merryn
Publicado 2021

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

por Levin, Myron J, Ustianowski, Andrew, Thomas, Steven, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Houlihan, Catherine F, Menendez-Perez, Ibrahim, Pollett, Simon, Arends, Rosalinda H, Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J, Koh, Gavin C K W, Ivanov, Stefan, Near, Karen A, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N, Esser, Mark T
Publicado 2022

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

por Madhavan, Meera, Ritchie, Adam J., Aboagye, Jeremy, Jenkin, Daniel, Provstgaad-Morys, Samuel, Tarbet, Iona, Woods, Danielle, Davies, Sophie, Baker, Megan, Platt, Abigail, Flaxman, Amy, Smith, Holly, Belij-Rammerstorfer, Sandra, Wilkins, Deidre, Kelly, Elizabeth J., Villafana, Tonya, Green, Justin A., Poulton, Ian, Lambe, Teresa, Hill, Adrian V.S., Ewer, Katie J., Douglas, Alexander D.
Publicado 2022

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

por Ahani, Bahar, Tuffy, Kevin M., Aksyuk, Anastasia A., Wilkins, Deidre, Abram, Michael E., Dagan, Ron, Domachowske, Joseph B., Guest, Johnathan D., Ji, Hong, Kushnir, Anna, Leach, Amanda, Madhi, Shabir A., Mankad, Vaishali S., Simões, Eric A. F., Sparklin, Benjamin, Speer, Scott D., Stanley, Ann Marie, Tabor, David E., Hamrén, Ulrika Wählby, Kelly, Elizabeth J., Villafana, Tonya
Publicado 2023